ReviewAsian journal of urology2025
Deciphering riddles in molecular subtyping of bladder cancer.
Review in Asian journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Multi-omics analysis identifies CKLF as a promoter for HCC progression by regulating the AKT, ERK pathways, and infiltrating immune cells.Translational oncology · 2026Article
- Integrating whole-genome bisulfite sequencing and TCGA data reveals methylation patterns associated with the MTHFR 677 C > T Variant.Scientific reports · 2026Article
- Machine learning-based identification of basement membrane-related signature to predict recurrence and immunotherapy benefit in bladder cancer.Immunologic research · 2026Article
- Review
- Complete pathological response in patients with bladder cancer: predictors and outcomes.Therapeutic advances in urologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Bladder cancer (BCa) is a prevalent malignant tumor in the urinary system. Molecular subtyping, utilizing molecular characteristics, represents a novel classification system that has demonstrated its efficacy in tumor diagnosis and treatment. Given the critical role of molecular subtyping in the BCa treatment, acquiring a comprehensive understanding is imperative for guiding treatment decisions, optimizing risk assessment systems, and ultimately improving patient prognosis. Methods: In this review, we provide a comprehensive overview of the research progress in molecular subtyping of BCa, with a primary focus on discussing its utility in guiding various treatment modalities including neoadjuvant chemotherapy, neoadjuvant immunotherapy, and targeted therapy. In addition, this review also covers the trimodality treatment, antibody-drug conjugates, and the treatment of small cell BCa. Results: We present a comprehensive overview of the responsiveness or resistance of different molecular subtypes of BCa to various therapeutic modalities. The basal subtype demonstrates favorable sensitivity to neoadjuvant chemotherapy across multiple classification systems, whereas the luminal infiltrated subtype exhibits potential susceptibility to immunotherapy. In terms of targeted therapy, the basal-like and the basal/squamous subtypes in some classifications have shown notable responsiveness to epidermal growth factor receptor-targeted therapy. Moreover, the luminal subtype in the University of Texas M.D. Anderson Cancer Center classification, the luminal papillary subtypes according to the Cancer Genome Atlas Research Network classification in 2017, and the luminal unstable type in the 2019 Molecular Subtyping classification show potential for the fibroblast growth factor receptor 3-targeted treatment. Conclusion: The significance and impact of BCa molecular subtyping in guiding treatment, evaluating progression, and predicting prognosis are increasingly acknowledged. Accurate subtyping and broad application can bring good benefits to clinical decision-making, risk assessment, and prognostic evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.